Drug Profile
GDC 0623
Alternative Names: GDC-0623; RG-7420Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Genentech
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 01 Aug 2014 Genetech completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease) in USA (NCT01106599)
- 16 Mar 2012 Genentech is enrolling patients in its phase I trial for Solid tumours (metastatic, late-stage disease) in the USA (NCT01106599)
- 30 Apr 2010 Phase-I clinical trials in Solid tumours (Metastatic, Late-stage disease) in USA (PO)